Biography

Prof. Aron D. Mosnaim

Rosalind Franklin University of Medicine and Science, USA


Email: [email protected]


Qualifications

1977 RPh., State of Illinois Pharmacy Board License 051-032662

1969 Ph.D.,Strathclyde University, Glasgow, Great Britain, Organic Chemistry

1962 Pharm.D., University of Chile, Santiago, Chile


Publications (Selected)

  1. Mosnaim, A. D., Wolf, M. E., III. O’Donnell, J. J., & Hudzik, T. (2020). β-Phenylethylamine and various monomethylated and para-halogenated analogs. Acute toxicity studies in mice. Drug and Chemical Toxicology, 43(4), 369-372.
  2. Wolf, M. E., & Mosnaim, A. D. (2016). Baclofen-Induced Manic Symptoms: Case Report and Systematic Review. Psychosomatics, 58(1), 94-94.
  3. Mosnaim, A. D., Hudzik, T., & Wolf, M. E. (2015). Behavioral effects of β-phenylethylamine and various monomethylated and monohalogenated analogs in mice are mediated by catecholaminergic mechanisms. American Journal of Therapeutics, 22(6), 412-422.
  4. Mosnaim, A.D.,Hudzik, T. and Wolf, M.E.: Analgesic effects of β-phenylethylamine and various methylated derivatives in mice. Neurochem Res. 39(9):1675-80, 2014. DOI: 10.1007/s11064-014-1354-7.
  5. Mosnaim, A.D.,Maturana, P., Callaghan, O.H. and Wolf, M.E.: Changes in plasma methionine-enkephalin levels associated with a cluster headache episode. American J. Therapeutics. 20(5):463-468, 2013. PMID: 23353772.
  6. Perlmuter, L.C, Sarda, G, Casavant, V. and Mosnaim A.D.: A review of the etiology, associated comorbidities, and treatment of orthostatic hypotension. American J. Therapeutics.20(3):279-291, 2013. PMID: 23656967.
  7. Mosnaim, A.D.,Callaghan, O.H., Hudzik, T. and Wolf, M.E.: Rat brain-uptake index for phenylethylamine and various monomethylated derivatives. Neurochemical Research 38(4):842-846, 2013. PMID: 23389662.
  8. Mosnaim, A.D.,Maturana, P, Puente, J. and Wolf, M.E.: Decreased plasma methionine-enkephalin levels in cluster headache patients. American J. Therapeutics.  19(3):174-179, 2012.
  9. Perlmuter, L.C., Sarda, G., Casavant, V., O’Hara, K.,Hindes, M., Knott, PT. and Mosnaim, A.D.: A  review of orthostatic blood pressure regulation and its association with mood and cognition. Clinical Autonomic Research. 22(2):99-107, 2012.
  10. Mosnaim, A.D., FuCheng, C. and Wolf, M.E.: Degradation kinetics of methionine-enkephalin by human cerebrospinal fluid. In vitro studies. American J. Therapeutics. 18:9-13, 2011.
  11. Mosnaim, A.D., Puente, J. and Wolf, M.E.: Biological correlates of migraine and cluster headaches: an overview of their potential use in diagnosis and treatment. Pragmatic and Observational Research. 1:25-32, 2010.
  12. Mosnaim, A.D., Abiola, R., Wolf, M.E. and Perlmuter, L.C.: Etiology and risk factors for developing orthostatic hypotension. American J. Therapeutics. 17(1):86-91, 2010.
  13. Mosnaim, A.D., Saavedra, R. and Wolf, M.E.: Bacitracin-sensitive aminopeptidase(s) degradation of methionine-enkephalin by human brain putamen and hippocampus preparations. Inhibition by phenothiazine drugs. American J. Therapeutics. 16:512-516, 2009.
  14. Puente, J., Jaque, M.P., Carrasco, C., Cruz, C., Valenzuela, M.A., Wolf, M.E. and Mosnaim A.D.:Triptan drugs, natural killer cell cytotoxicity and neutrophils pro-matrix metalloproteinase-9 secretion. Headache. 40(10): 1482-1489, 2008.
  15. Mosnaim, A.D.,Nguyen, T.D., Puente, J. and Wolf,, M.E.:Degradation kinetics of methionine5-enkephalin by select brain areas from patients with chronic schizophrenia.American J. Therapeutics. 15(2):126-130, 2008.
  16. Mosnaim, A.D.,Nguyen, T.D., Tse, R, Puente, J., Couceyro, P. and Wolf, M.E.: In vitro methionine-enkephalin degradation kinetics by human brain preparations. Neurochemical Research. 33(1):81-86, 2008.
  17. Puente, J., Mosnaim, A.D. and Wolf, M.: Stress, Opioid Peptides and the Immune Response, in Stress, Cytokines and the Immune Response (N. P. Plotnikoff, R.E. Faith, A.J. Murgo and R.A. Good, eds). CRC Press, Taylor & Francis Group, New York, pp.125-142, 2006.
  18. Mosnaim, A.D., Ranade, V.R., Wolf, M.E., Puente, J. and Valenzuela, M.A.: Phenothiazine molecule provides the basic chemical structure for various classes of pharmacotherapeutic agents. American J. Therapeutics. 13:261-273, 2006.
  19. Valenzuela, M.A., Cartier, L.A., Mosnaim, A.D., Wolf, M.E., Ketllun, A.M., Collados, C. and Garcia, L.: Proteinases and Prion Diseases, in Proteases in the Brain (U. Lendeckel and N. Hooper, eds). Springer, USA, pp. 179-202, 2005.
  20. Mosnaim, A.D.,Puente, J., Hoang, C., Ranade, V. and Wolf, M.E.: Inhibition of human plasma leucine-enkephalin aminopeptidase hydrolysis by various endogenous peptides and a select number of clinically used drugs. American J. of Therapeutics. 11:459-465, 2004.
  21. Kettlun, A.M., Collados, C., García, L., Cartier, L.A., Wolf, M.E., Mosnaim, A.D. and Valenzuela, M.A.: Matrix metalloproteinases profile in patients with Creuztfeldt-Jakob Disease. International Journal of Clinical Practice. 57(6):475-478, 2003.
  22. Miranda, D., Puente, J., Blanco, L., Jara, P., Wolf, M.E. and Mosnaim, A.D.: Lysis of Salmonella typhi intracellularly-infected U.937 cells by human natural killer cells. Effect of protein kinase inhibitors. American J. Therapeutics. 10:32-39, 2003.
  23. Mosnaim, A. D., Puente, J., Saavedra, R., Diamond, S. and Wolf, M.: In vitro human plasma leucine-enkephalin degradation is inhibited by a select number of drugs with the phenothiazine molecule in their chemical structure. Pharmacology. Intern J Experim and Clin Pharmacology. 67(1):6-13, 2003.
  24. Mosnaim, A.D.:Invited editorial. Cephalalgia 22(7): 614-615, 2002.
  25. Miranda, D., Puente, J., Blanco, L., Jara, P., Wolf, M.E. and Mosnaim, A.D.: Human natural killer cell lysis of Salmonella typhi intracellularly-infected U 937 cells. Res. Commun. Molec. Pathol. Pharmacology . 111:3-12, 2002.
  26. Puente, J., Blanco, L., Carrasco, C., Miranda, D., Wolf, M.E. and Mosnaim, A.D.: Effect of Salmonella-infected human monocytes on natural killer cell cytotoxicity. In vitro studies. International Immunopharmacology. 1:1285-1293, 2001.
  27. Mosnaim, A. D., Wolf, M. E., Tao, D.N., Puente, J., Freitag, and Diamond, S.: Degradation kinetics of leucine-enkephalin by plasma samples from healthy controls and various patient populations. In vitro drug effects. American J. Therapeutics. 7:185-194, 2000.
  28. Puente, J., Blanco, B., Montoya, M., Miranda, D., Contreras, I., Vinés E., Wolf, M.E. andMosnaim, A.D.: Effect of S. Typhi wild type and O-antigen mutants on human natural killer cell activity. Intern. J. Clin. Immunology. 355-364, 2000.
  29. Wolf, M. E., Ranade, V., Molnar, J., Somberg, J. and Mosnaim, A. D.: Hypercalcemia, arrhythmia and mood stabilizers. J. Clin. Psychopharmacology. 20(2):260-264, 2000.
  30. Ranade, V., Molnar, J., Khokher, T., Agarwal, A., Mosnaim, A.D. and Somberg, J.: Effect of angiotensin-converting enzyme therapy on QT interval dispersion. American J. Therapeutics. 6:257-261, 1999.
  31. Valenzuela, M. A., Cartier, L., Collados, L., Kettlun, A. M., Araya, F., Concha, C., Flores, L., Wolf, M. E. and Mosnaim, A. D.: Gelatinase activity of matrix metalloproteinases in the cerebrospinal fluid of various patient populations. Res. Comm. Chemical Pathology Pharmacology. 104(1):42-52,1999.
  32. Mosnaim, A.D., Kulaga, H., Adams, J.A., Wolf, M.E., Freitag, F. and Diamond. S.: Flow cytometric analysis of lymphocyte subsets in migraine patients during and outside of an acute headache attack. Cephalalgia. 18(4):197-201, 1998.
  33. Karoum, F., Wolf, M.E. and Mosnaim, A.D.: Effects of the administration of amphetamine, either alone or in combination with reserpine or cocaine, on regional brain beta-phenylethylamine and dopamine release. American J. Therapeutics. 4(9-10):333-342, 1997.
  34. Sepúlveda, C., Puente, J., Weinstein, C., Wolf, M.E. and Mosnaim, A. D.: Enhancement of natural killer cell activity in HIV-1 infected subjects by a mixture of the calcium ionophore A23187 and the phorbol ester TPA. Lack of response to a similar challenge with interleukin-2 or alpha-interferon. American J. Therapeutics. 4(11-12):413-421, 1997.
  35. Mosnaim, A.D., Freitag, F., Ignacio, R., Salas, M.A., Karoum, F., Wolf, M.E. and Diamond, S.: Apparent lack of correlation between tyramine and phenylethylamine content and the occurrence of food-precipitated migraine. Reexamination of a variety of food products frequently consumed in theUnited States and commonly restricted in tyramine-free diets. Headache Quarterly. Current Treatment and Research. 7(3):239-249, 1996.
  36. Mosnaim, A.D., Wolf, M.E., Curr, M., Mosnaim, J.M., Freitag, F. and Diamond, S.: Myths in migraine research: 1. Migraine and cluster headache patients are characterized by significant alterations in platelet monoamine oxidase activity. Headache Quarterly. Current Treatment and Research.7(3):225-234, 1996.
  37. Puente, J., Diaz, M.A., Salas, M.A., Miranda, D., Gaggero, A., Wolf, M.E. and Mosnaim, A.D.: Studies of natural killer cell activity in a drug-free, healthy population. Response to a challenge with taxol, estramustine and lipopolysaccharide. International J. Clinical Pharmacolology Therapy.33(8):457-461, 1995.
  38. Mosnaim, A.D.: Biochemical and immunological studies in migraine and cluster headaches. In: Symposium "New and Old Therapies of Vascular Headaches: Immune Approaches and Serotonin Receptors in Therapy". (A.D. Mosnaim proceedings ed). Headache Quarterly. Current Treatment and Research. 34-38: 1994.
  39. Mosnaim, A. D.: Symposium participant "New and Old Therapy for Vascular Headaches" (proceedings edited by Journal's staff). P&T (Pharmacy and Therapeutics. A Peer Reviewed Journal for Formulary Management). 18(6):575-582, 1993.
  40. Mosnaim, A.D., Wolf, M. E., Maturana, P., Mosnaim, G., Puente, J., Kucuk, O. and Gilman-Sachs, A.: In vitro natural killer cell activity in post traumatic stress disorder patients. Response to methionine-enkephalin challenge. Immunopharmacology. 25:107-116, 1993.
  41. Mosnaim, A.D.: Role of enkephalins in the regulation of pain in migraine and cluster headaches. National Headache Foundation Letter, pp.13, Summer 1992.
  42. Mosnaim, A.D., Huprikar, S., Wolf, M.E., Freitag, F. and Diamond, S.: Studies of platelet monoamine oxidase activity in female migraineurs. An old story revisited, in F.C. Rose (ed.): New Advances in Headache Research: 2, London:  Smith-Gordon and Co. Ltd. 135-139, 1991.
  43. Wolf, M.E. and Mosnaim, A.D. (eds.): Post Traumatic Stress Disorder:  Etiology, Phenomenology and Treatment.American Psychiatric Press, Washington, DC 1990.
  44. Wolf, M.E. and Mosnaim, A.D. (eds.): Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects. American Psychiatric Press, Washington, DC 1988.
  45. Ayre, S., Skalestski, B. and Mosnaim, A.D.: Blood-brain barrier passage of azidothymidine in rats: effects of insulin. Res. Comm. Chemical Pathology Pharmacology. 63(1):45-52, 1989.
  46. Mosnaim, A.D., Callaghan, O.H. and Wolf, M.E.: Hydroxylation of phenylethylamine by rat liver preparations. Gen. Pharmacology. 19(5):729-733, 1989.
  47. Diamond, S., Mosnaim, A.D., Freitag, F., Wolf, M.E., Lee, G. and Solomon, G.: Plasma methionine-enkephalin in patients with cluster headache, in F.C. Rose (ed.): Advances in Headache Research, Vol. 4, London: John Libbey & Co. Ltd. 4: 209-219, 1987.
  48. Wolf, M.E., Alavi, A. and Mosnaim, A.D.: Aids related complex in a Vietnam Veteran with drug abuse. Res. Comm. Substance Abuse. 8:117-123, 1987.
  49. Wolf, M.E. and Mosnaim, A.D.: Lithium and molindone interactions: pharmacokinetic studies. Res. Comm. Psychol. Psychiatry Behavior. 11(1):23-28, 1986.
  50. Mosnaim, A.D., Chevesich, J., Wolf, M.E., Freitag, D.O. and Diamond, S.: Plasma methionine-enkephalin. Increased levels during a migraine episode. Headache. 26(6):278-281, 1986.
  51. Wolf, M.E., Mosnaim, A.D., Owens, R., Paulos, M. and Hoffman, H.E.: Molindone pharmacokinetics in psychiatric patients. Res. Comm. Psychol. Psychiatry Behavior. 10(3):215-220, 1985.
  52. Paulos, M.A., Mosnaim, A.D., Wolf, M.E. and Tessel, R.E.: Phenylethylamine, phenylacetic acid and methionine enkephaline levels in humans following profound acute stress, in A. Boulton, G. Baker,W. Dewhurst and M. Sandler (eds.): Neurobiology of Trace Amines. New Jersey: Humana Press 563-569, 1984.
  53. Mosnaim, A.D., Wine, R., Diamond, S. and Wolf, M.E.: Plasma methionine enkephalin levels during migraine episodes, in F.C. Rose (ed.): Progress in Migraine Research, Vol. 2. London, England: Pitman Book Ltd. 151-161, 1984.
  54. Mosnaim, A.D., Wolf, M.E., and Szanto, P.: Butaperazine effects on plasma methionine-enkephalin levels in patients with tardive dyskinesia. Res. Comm. Substance Abuse. 5(4):313-316, 1984.
  55. Wolf M.E. and Mosnaim A.D.: Tardive dyskinesia subtypes. Hospital Community Psychiatry.35(8):828-830, 1984.
  56. Wolf, M.E. Chevesich, J.E., Lehrer, E. and Mosnaim, A.D.: The clinical association of tardive dyskinesia and drug induced Parkinsonism. Biol. Psychiatry. 13(10):1181-1188, 1983.
  57. Wolf, M.E., Keener, S., Mathis, P. and Mosnaim, A.D.: Phenylethylamine-like properties of Baclofen. Neuropsychobiology. 9:219-22, 1983.
  58. Wolf, M.E. and Mosnaim, A.D.: Phenylethylamine in neuropsychiatric disorders. Gen. Pharmacology 14(4):385-390, 1983.
  59. Mosnaim, A.D., Wine, R., Karoum, F., Diamond, S. and Wolf, M.E.: Methionine enkephalin, phenylethylamine, phenylacetic acid, platelet monoamine oxidase and prolactin in plasma of migraine patients. Clinical Pharmacology Therapeutics. 31(2): 251-252, 1982.
  60. Mosnaim, A.D., Callaghan, O.H. and Wolf, M.E.: Determination of non-catecholic phenylethylamines and monomethylated derivatives of phenylethylamines. J. Chromatography. Biomedical Applications 224:481-487, 1981.
  61. Mosnaim, A.D.and Wolf, M.E. (eds.): Non-catecholic Phenylethylamines. Part 2: Phenylethanolamine, Tyramines and Octopamine. Marcel Dekker, Inc., New York, 1980.
  62. Alcorn, W.C., Cromarty, F.M., Flood, J., Mancilla, J.M., Mosnaim, A.D., Nonhebel, D.C. and Scullion, I.: Reactions of copper (II) halides with aromatic compounds. Part XIII. The mechanisms of halogenation of some substituted 9-methylanthracenes. J. Chemical Research. 3:102-103, 1980.
  63. Mosnaim, A.D., Wolf, M.E., Huprikar, S., Singh, S.P. and Zeller, E.A.: Reduced monoamine oxidase activity in blood platelets from insulin-dependent diabetics. Diabetes. 28:455-456, 1979.
  64. Mosnaim, A.D.and Wolf, M.E. (eds.): Non-catecholic Phenylethylamines. Part 1: Phenylethylamine: Biological Mechanisms and Clinical Aspects. Marcel Dekker, Inc., New York, 1978.
  65. Ungar, F., Mosnaim, A.D., Ungar, B. and Wolf, M.E.: Preliminary studies of the sodium borohydride stabilizable binding of phenylethylamine and tyramine to brain preparations. Res. Comm. Chemical Pathol. Pharmacol. 19:427-434, 1978.
  66. Mosnaim, A.D., Edstrand, D.L., Wolf, M.E. and Silkaitis, R.P.: Evidence for an enzymatic p-tyramine-dehydroxylating system in rabbit brain preparations in vitro. Biochemical Pharmacology.26:1725-1728, 1977.
  67. Pedemonte, W.A., Mosnaim, A.D. and Bulat, M.: Penetration of phenylacetic acid across the blood-cerebrospinal fluid barrier. Res. Comm. Chemical Pathol. Pharmacol. 14(1):111-116, 1976.
  68. Silkaitis, R.P. and Mosnaim, A.D.: Pathways linking L-phenylalanine and 2-phenyl-ethylamine with p-tyramine in rabbit brain. Brain Research. 114:105-115, 1976.
  69. Borison, R.L., Mosnaim, A.D. and Sabelli, H.C.: Qualification of brain 2-phenylethylamine content by gas-liquid chromatography and its modification by marihuana. Clinical Research. 23: 550A, 1975.


Profile Details

https://www.rosalindfranklin.edu/academics/faculty/aron-d-mosnaim/
https://scholar.google.com/citations?hl=en&user=Pee17WcAAAAJ&view_op=list_works&sortby=pubdate

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top